Total joint arthroplasty is associated with significant blood loss, that could result in the need of blood transfusions. Several techniques are being utilised to limit the volume of blood loss, in order to avoid transfusion. In this review, we look at blood loss in total joint arthroplasty and the perioperative strategies to limit the loss of blood. With the use of tranexamic acid gaining popularity, we analyse the published literature on its use in patients undergoing total joint arthroplasty. We have found that published studies favour using tranexamic acid in total joint arthroplasty as a safe and effective method of reducing blood loss.
Introduction
Total joint arthroplasty (TJA) is a major common orthopaedic procedure aimed at fixing deformities, managing severe osteoarthritis and dealing with fractures. According to the National Joint Registry 15th annual report [NJR 2018] , approximately 2,308,950 total joint arthroplasties were performed in the past 14 years in the UK. With the numbers of performed surgeries increasing every year worldwide (Schwartz & Lange 2017), TJA accounts for approximately 9.8% of the transfused red blood cells, making it the leading cause of transfusion in surgical patients (Shortt et al 2009) . It has been estimated that on average, 500ml to 1600ml of blood is anticipated to be lost in these operations due to soft tissue dissection, reaming and osteotomy of the long bones (Nadeau et al 2015 , Hill et al 2018 . In addition, tissue plasminogen activator is highly elevated in the first day of surgery, which promotes increased fibrinolytic activity and therefore contributes to postoperative anaemia (Stoicea et al 2018) .
Factors increasing the risk of intraoperative blood loss and postoperative transfusion
Risk factors that contribute to blood loss and transfusion include body mass index (BMI), low preoperative haemoglobin, males, age >75, hypertension, surgical technique, and prolonged intraoperative time (Carling et al 2015 , Liu et al 2016 . It has been noted that patients with a haemoglobin (Hb) of <13g/dL are at least five times more likely to receive transfusion as opposed to a Hb of >15g/dl (Hatzidakis et al 2000 , Guerin et al 2007 . Furthermore, it was believed that larger volume of blood loss is associated with a low BMI. However, Prasad et al (2007) and Hrnack et al (2012) concluded that BMI does not affect volume of blood lost in TJA procedures.
Consequences of blood loss in total joint arthroplasty
Majority of patients undergoing TJA suffer from comorbidities, and the resulting blood loss potentiates the risk of developing severe cardiopulmonary complications (Hill et al 2018) . As a result of increased blood loss during TJA, a large proportion of patients (approximately 10-32%) need blood transfusion (Stoicea et al 2018) . This can be associated with the risk of infection, prolonged hospital stay, huge financial burden on the hospital, and increased morbidity and mortality (Carling et al 2015 , Stoicea et al 2018 . It is because of these implications that it is of utmost importance that blood conserving strategies are well thought of.
Preoperative assessment for total joint arthrolpasty
Since TJA carries a significant risk of blood loss, it is imperative to determine the preoperative Hb level a month prior to the surgery in order to allow for sufficient time to investigate and correct the anaemia (Goodnough et al 2011) . Investigations should include full blood count (FBC) to check the Hb levels, and if found to be low (Females <12g/dl, males <13g/dl) then iron studies should be conducted to investigate for iron deficiency anaemia (Goodnough et al 2011) . In addition, serum creatinine and glomerular filtration rate (GFR) need to be tested preoperatively to assess the renal function, to allow for dose adjustment of medications such as tranexamic acid (TXA).
In the present time, literature suggests limited benefit from performing coagulation studies on surgical outcome (Thiruvenkatarajan et al 2014). However, it is important to take an extensive bleeding history, which composes family history of coagulopathies, and excess bleeding during procedures. Also, a drug history should be obtained to find out if the patient is on any anticoagulants. If the history is significant then a coagulation study of prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet count should be carried out.
Intraoperative techniques aimed at reducing blood loss
Several methods have been utilised in an attempt at reducing blood loss and subsequent anaemia, and these include the use of tourniquets, autologous blood transfusion, intraoperative red cell salvage, antifibrinolytic drugs and erythropoietin.
A tourniquet has been used for a long time in orthopaedic surgery; however, it has been associated with neurovascular damage and metabolic disturbances (Parvizi & Diaz-Ledezma 2013 , Jiang 2015 . In addition, Cao et al (2018) concluded that the use of tourniquet in TJA was associated with greater risk for transfusion. It has also been noted that after the release of a tourniquet there is increased fibrinolytic activity, which promotes further blood loss (Aglietti et al 2000) .
Autologous blood transfusion can be utilised for anaemic patients given that there is adequate time to process red blood cells (Boutsiadis et al 2017). Intraoperative red cell salvage is beneficial when there is 1L of blood loss; its efficiency is potentiated when combined with TXA as per the NICE guidelines (Thakrar et al 2017). However, Schnurr et al (2018) concluded that there is no beneficial effect in the utilisation of autologous transfusion drains. Additionally, a case control prospective study (Yin et al 2017) concluded that the use of a closed-suction drain in total knee arthroplasty does not confer any significant advantage, and that its use is redundant. This was further confirmed in a large meta-analysis (Zhang et al 2018). Furthermore, the utilisation of TXA in the enhanced recovery program leads to a decrease in the transfusion rates, and therefore reduces the dependency on drains (Khan et al 2014).
TXA, and e-aminocaproic acid (EACA) belong to the same antifibrinolytic class of drugs and have proven to be effective in minimising blood loss (Nadeau et al 2015 , Ramkumar et al 2018 . However, TXA has been a more popular choice due to its higher affinity and cost efficiency when compared to EACA. Erythropoietin has been proven successful in managing low preoperative Hb; however, it is associated with a high financial cost (Bedair et al 2015).
Tranexamic acid
Current practice and literature are moving in the direction of utilizing pharmacological agents to reduce intraoperative and postoperative bleeding. Antifibrinolytic drugs are now being utilised as an alternative to routine blood conserving methods in order to achieve homeostasis. From these drugs, TXA, a synthetic lysine derivative, is of particular interest and has been extensively used in the medical and surgical field (Nicoleta et al 2018).
As part of the normal coagulation cascade, plasminogen in the presence of a tissue plasminogen activator promotes finbrinolysis. When plasminogen interacts with fibrin, it gets converted into plasmin, which degrades the cross-linked fibrin and breaks down the clot. Due to the structural resemblance of TXA to lysine, this allows it to competitively bind to the plasminogen binding site, which in turn inhibits the breakdown of fibrin molecules and therefore allows for haemostasis to take place (Nicoleta et al 2018). TXA is excreted by the renal system owing to the fact that it is not bound by protein in the systemic circulation, which means adjustments to the dose is necessary in patients with impaired renal function (Nadeau et al 2015).
Tranexamic acid literature review and controversies
In a published study by Fillingham et al (2018), a metaanalysis looked into 1 moderate quality and 82 high quality studies on TXA, suggesting that the use of intravenous (IV), topical, and oral TXA to be an effective strategy in reducing blood loss and the need for blood transfusion in TJA. The risk of blood transfusion in total knee arthroplasty was reduced by 81% using IV TXA, by 66% using topical TXA and by 61% using oral TXA when compared to placebo. Similarly, in total hip arthroplasty, IV and topical TXA were found to minimise the need of transfusion by 60% and 71%, respectively compared to placebo. Fillingham et al (2018), however, concluded that oral TXA in total hip arthroplasty did not significantly reduce the risk of blood transfusion compared to placebo. Stoicea et al (2018) concluded in their study that the use of 1-2 gram of TXA (IV or intra-articular [IA]) significantly decreased the drop in Hb postoperatively, and did not increase the risk of adverse events. A clinical trial by Oremus et al (2014) reinforced the beneficial outcomes of IV TXA in total knee arthroplasty, concluding that 600ml of blood were spared when TXA was used in the perioperative setting as opposed to the control group. Another meta-review (Tian et al 2017) analysed data from four studies published on the effect of TXA in revision total knee arthroplasty. The analysis involved a total of 667 patients, one group received TXA and a control group without TXA. It was concluded that there is a significant reduction in the need for blood transfusion amongst patients given TXA, with 14.5% of these requiring transfusions compared to 33.8% in the control group. Also, it was demonstrated that there is considerable decrease in drainage volume, and haemoglobin level postoperatively.
Safety concerns
The use of TXA in TJA has not yet been supported by the National Institute for Health and Care Excellence or British Orthopaedic Association guidelines (Hill et al 2018) . This is due to the lack of comprehensive review and analysis of existing literature. Also, safety of TXA has been questioned as it was linked to deep vein thrombosis, pulmonary embolism, cerebrovascular accident and myocardial infarction (Stoicea et al 2018). However, according to a Cochrane Review (Henry et al 2011) and a study published by Poeran et al (2014), it was concluded that TXA is not associated with these adverse health effects. This was reinforced and strongly supported by Fillingham et al (2018) in which multiple individual studies were reviewed to investigate the adverse thromboembolic events related to TXA. In addition, multiple retrospective studies have confirmed the safety of TXA in lower TJA in the presence and absence of significant thromboembolic history (Fillingham et al 2018) . Also, in view of the NICE guidelines (NICE 2018) recommending the use of aspirin in primary total knee arthroplasty, it is worth mentioning that Heller et al (2016) concluded that it is safe and efficacious to use both drugs concurrently.
Route of administration
Hamlin et al (2015) and Chen et al (2016) have suggested that IA administration of TXA to be a more effective method in limiting blood loss and the need of transfusion when compared to the IV route. However, a meta-analysis of 31 high quality studies and an extended network meta-analysis by Fillingham et al (2018) concluded that there is no superior method of TXA administration. Wong et al (2010) in his clinical trial demonstrated equal success in reducing blood loss in total knee replacement by 25% when using topical 1.5g and 3g TXA compared to the control group. This was further supported by Sarzaeem et al (2014) and Carvalho et al (2015) when they investigated the use of topical TXA at 1.5g and 3g. Lin et al (2012) and Barrachina et al (2016) investigated IV TXA at different doses in total hip and knee arthroplasty, and their results did not show any considerable benefit of using higher doses.
Comparing high and low dose tranexamic acid
Finally, a network meta-analysis (Filingham et al 2018) comparing high dose TXA [IV (>20mg/kg or >1g), oral (>1.5g)] and low dose TXA [IV (<20mg/kg or 1g), oral (1.5g)] concluded that there is no substantial change in blood loss or blood transfusion. In a meta-analysis (Filingham et al 2018) of six high quality studies comparing single dose IV TXA versus multiple doses IV TXA in primary total knee arthroplasty, it was concluded that there is no proven benefit of one modality over the other. In total hip arthroplasty, multiple individual studies have proven that there is no superior benefit of multiple IV TXA doses (Filingham et al 2018).
Time of administration
Ekb€ ack et al (2000) demonstrated lower volumes of blood loss when administering IV TXA before beginning the surgery. A direct meta-analysis (Filingham et al 2018) on five high quality studies on total knee arthroplasty demonstrated that administering a dose of IV TXA prior to skin incision significantly decreased the need for blood transfusion. However, there was no notable change in calculated blood loss when compared to administering IV TXA after incising the skin. A similar network meta-analysis was conducted on total hip arthroplasty, which did not show any considerable difference in terms of TXA timing administration.
Despite the controversy regarding the most beneficial time of administering TXA, the recommendation by Filingham et al (2018) is to give TXA prior to performing the skin incision. This is supported by the fact that upon deflating the tourniquet in a total knee arthroplasty there is an enhanced fibrinolytic response, which leads to bleeding into the adjacent tissues and joint. Administering TXA prior to skin incision could allow for optimum levels to be reached within the joint prior to deflating the tourniquet, and therefore counteracting the hyperfibrinoloysis (Nadeau et al 2015).
Conclusion
In conclusion, current literature favours the use of tranexamic acid as a blood conserving modality in total joint arthroplasty. It has been proven to significantly and safely reduce total blood loss during these procedures and the need for transfusion, which in turn reduces the risk of postoperative complications. Despite this, more well-designed studies need to be conducted to provide a definitive dose, route and timing of tranexamic acid administration, which will have a positive impact on the success of total joint arthroplasty procedures.
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